Publication details
Prognostic impact of 1q21 amplification for newly diagnosed and relapsed/refractory multiple myeloma patients enrolled in Brno, Czech Republic.
| Authors | |
|---|---|
| Year of publication | 2007 |
| Type | Article in Proceedings |
| Conference | From cell sorting to plasma cell identification and detection chromosomal aberrations in multiple myeloma. Abstract and Application Manual |
| MU Faculty or unit | |
| Citation | |
| Field | Genetics and molecular biology |
| Keywords | multiple myeloma; 1q21 amplification; fluorescence in situ hybridisation; DNA probe; Velcade; Thalidomide |
| Description | Introduction Fluorescence in situ hybridisation (FISH) has become a powerful technique for prognostic assessment in multiple myeloma (MM). Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma. A total of 88 patients enrolled in Faculty Hospital Brno, Czech Republic have been analyzed by FISH for presence of 1q21 amplification (Amp(1q21)). Impact of Amp(1q21) in clinical parameters (treatment responses and selected "end-point" intervals) in 39 patients with newly diagnosed MM enrolled in CMG2002 trial (4 cycles of VAD followed by high-dose therapy - melphalan 200mg/m2 supported by autologous stem cell transplantation (ASCT)) were statistically analysed. In a similar way a subset of 49 relapsed patients with at least 1 prior treatment line were analysed separatelly in groups divided according to treatment based regimen (Thalidomide or Velcade). See Table 1 for patients baseline characteristics. Results valid for newly diagnosed patients: Amp(1q21) was found in 41% (16/39) patients. Clinical parameters valid for patients with Amp(1q21) versus patients lacking Amp(1q21) were as follows: overall response rate (ORR) achieved 87.5% (14/16) vs. 91.3% (21/23) patients (p=0.404); overall survival (OS) median was 22.4 months vs. not yet reached (NR) (p=0.022); time to progression (TTP) median was 16.1 months vs. NR (p=0.010); progression-free survival (PFS) median was 15.6 vs. 25.2 months (p=0.023); and duration of response (DOR) median was 15.9 months vs. NR (p=0.048). Results valid for relapsed patients: Amp(1q21) was found in 61.2% (30/49) patients. Thalidomide based regimen group Amp(1q21) was found in 40.7% (11/27) patients. Clinical parameters valid for patients with Amp(1q21) versus patients lacking Amp(1q21) were as follows: ORR achieved 83.3% (5/6) vs. 80% (8/10), (p=0.868); OS median was 6.6 months vs. NR (p=0.072); TTP median was 12.1 vs. 8.2 months (p=0.269); and PFS median was 11.7 vs. 8.2 months (p=0.484). Velcade based regimen group Amp(1q21) was found in 86.4% (19/22) patients. Clinical parameters valid for patients with Amp(1q21) versus patients lacking Amp(1q21) were as follows: ORR achieved 50% (7/14) vs. 66.7% (2/3), (p=0.316); OS median was NR vs. NR (p=0.937); TTP median was 8 months vs. NR (p=0.442); and PFS median was 6.5 months vs. NR (p=0.637). Conclusion In conclusion, patients with Amp(1q21) treated by ASCT have significant shorter PFS median (15.6 months) when compared with patients lacking Amp(1q21) with PFS median 25.2 months (p=0.023). There were found statistical significant difference in all named "end- point" intervals (OS, TTP, PFS and DOR) between patients with/without Amp(1q21) but not in ORR. This findings is in accordance with previously published work (Chang et al., 2006). Relapsed patients with Amp(1q21) treated by thalidomide based regimen show a trend towards the worst prognosis based on overall survival when compared with patients lacking Amp(1q21) suggesting that thalidomide probably cannot overcome negative prognostic impact of this aberration. None significant differences between clinical parameters of patients with/without Amp(1q21) treated with Velcade based regimen were observed. However these findings has to be confirmed on a larger cohort of patients. These data are valid for July 2007. Supported by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre (LC 06027), Masaryk University, Brno, Czech Republic, and by grant of Ministry of Education (MSM0021622415), Czech Republic, and grant of Ministry of Medicine (IGA NR9317-3), Czech Republic. |
| Related projects: |